

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201)

<http://guidance.nice.org.uk/TA/WaveR/110>

Dear Consultees and Commentators,

As you know the Appraisal Committee met on 3 July to consider the evidence for the above appraisal. After careful consideration, and in response to the points raised at the committee meeting, the Appraisal Committee has requested that additional information be collected and analyses undertaken by the Assessment Group (Centre for Reviews and Dissemination/Centre for Health Economics, University of York) before it provides its advice to the Institute. This information includes clinical characteristics of people with very severe allergic asthma currently treated with omalizumab, and the modelling of alternative assumptions on the mortality rates for very severe asthma, treatment duration, adverse effects of oral corticosteroid treatment, and carer benefits.

As a result an Appraisal Consultation Document (ACD) will not be issued at this time, as previously planned, and the timelines of the appraisal will be extended in order that the additional analysis can be undertaken and considered. It is our intention to hold the next discussion of this appraisal on the 3 October 2012, but this date is not confirmed at this time. We will ask the clinical and patient experts who came to the 3 July meeting if they can come to the next meeting for this appraisal.

Following the next Committee discussion of this topic an ACD would be issued followed by an ACD consultation and a further Committee meeting before a FAD will be issued.

We will not be consulting on the additional analyses produced by the Assessment Group before the next Committee meeting (see also sections 3.5.21 and 3.5.22 of our Guide to the Multiple Technology Appraisals Process - <http://www.nice.org.uk/media/42D/8C/MTAGuideLRFINAL.pdf>), but this information will form part of the evaluation report that will be published with the ACD consultation.

If you have any questions, please contact me.

Kind regards,

Jeremy

Jeremy Powell

Technology Appraisal Project Manager
National Institute for Health and Clinical Excellence
MidCity Place | 71 High Holborn | London WC1V 6NA | United Kingdom
Tel: 44 (0)20 7045 2248 | Fax: 44 (0)20 7061 9830

Web: <http://nice.org.uk>